Signaling pathways in the differentiating MoDCs obtained from healthy donors or myeloma patients. (A) Western-blot analysis showing protein levels of phosphorylated (p) and nonphosphorylated p38, MEK1/2, ERK1/2, and STAT3 in freshly isolated monocytes (day 0) and day-2–cultured cells from a healthy donor and a myeloma patient. (B) Effects of IL-6–neutralizing antibody (Ab), p38 inhibitor (P38I), or both on signaling pathways in myeloma patient–derived cells. (C) Effects of TCCM and p38 inhibitor on signaling pathways in normal MoDC progenitor cells from healthy donors. In all the experiments, day-2–cultured cells were examined. Representative results of 3 independent experiments are shown.